CMPS Compass Pathways |
$14.22
-6.3% |
|
COMP360 psilocybin
Therapy for treatment-resistant depression (TRD)
|
|
9/10/2026 - Provided Update
Compass Pathways plc announced the U.S. grant program recipients to create training programs for he…
Full Summary
|
PRLD Prelude Therapeutics |
$4.67
-8.3% |
-18.5%
 |
PRT13722
Oral KAT6A Selective Degrader
|
|
9/10/2026 - FDA Clearance
Prelude Therapeutics announced that the U.S. Food and Drug Administration (FDA) cleared the Company…
Full Summary
|
PRLD Prelude Therapeutics |
$4.67
-8.3% |
-18.5%
|
PRT13722
Oral KAT6A Selective Degrader
|
Target date: Q4 2026
|
9/10/2026 - Enrollment Update
Prelude Therapeutics Incorporated announced that the Company expects to begin enrolling patients in…
Full Summary
|
BLRX BioLineRx |
$2.57
+0.8% |
-4.5%
 |
GLIX1
treatment of recurrent and progressive glioblastoma
|
|
9/10/2026 - Abstract
BioLineRx Ltd. announced that two abstracts featuring GLIX1 have been accepted for presentation, in…
Full Summary
|
MDCX Medicus Pharma |
$0.16
-5.3% |
-51.3%
 |
SKNJCT-003
For the Treatment of Nodular Basal Cell Carcinoma
|
|
9/10/2026 - Provided Update
Medicus Pharma Ltd. y announced that an abridged Clinical Study Report (CSR) for SKNJCT-003 (NCT0660…
Full Summary
|
AGEN Agenus |
$6.89
+0.4% |
-0.1%
 |
BOT/BAL
In Metastatic MSS Colorectal Cancer
|
|
9/10/2026 - Presentation
Agenus Inc announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional ant…
Full Summary
|
CAMP CAMP4 Therapeutics |
$4.34
+0.2% |
-4.2%
 |
CMP-002
treat a broad range of genetic diseases
|
Phase 1/2
|
9/10/2026 - Authorization
CAMP4 Therapeutics Corporation announced the company has received authorization from the United Kin…
Full Summary
|
CAMP CAMP4 Therapeutics |
$4.34
+0.2% |
-4.2%
|
CMP-002
treat a broad range of genetic diseases
|
Target date: Q4 2026
|
9/10/2026 - Clinical Trial
CAMP4 Therapeutics Corporation announced that the Company anticipates initiation of the clinical tr…
Full Summary
|
LEGN Legend Biotech |
$19.19
-3.6% |
-7.1%
 |
Ciltacabtagene Autoleucel (cilta-cel)
Relapsed and/or Refractory Multiple Myeloma
|
|
9/10/2026 - Data Presentation
Legend Biotech Corporation announced that data from CARTITUDE-2 and real-world evidence will be pres…
Full Summary
|
CMPS Compass Pathways |
$14.22
-6.3% |
|
COMP360
for treatment resistant depression (TRD).
|
|
9/10/2026 - Provided Update
Fluence Selected by Compass Pathways as a recipient of its U.S. healthcare provider training grant p…
Full Summary
|
ONCY Oncolytics Biotech |
$0.77
-2.9% |
-6.3%
 |
Pelareorep
In Breast Cancer
|
|
9/10/2026 - Positive Results
Oncolytics Biotech® Inc. announced positive preclinical results evaluating pelareorep in combinatio…
Full Summary
|
OPTH Optimi Health |
$4.50
+3.4% |
-5.3%
 |
psilocybin-assisted therapy
for Major Depressive Disorder
|
Phase 2
|
9/10/2026 - Trial Initiation
Optimi Health Corp announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocy…
Full Summary
|
OPTH Optimi Health |
$4.50
+3.4% |
-5.3%
|
psilocybin-assisted therapy
for Major Depressive Disorder
|
Target date: H1 2027
|
9/10/2026 - Trial Initiation
Optimi Health Corp announced that the trial is planned to be initiated in the first half of 2027
Full Summary
|
OPTH Optimi Health |
$4.50
+3.4% |
-5.3%
|
psilocybin-assisted therapy
for Major Depressive Disorder
|
Target date: LATE 2027
|
9/10/2026 - Dose Update
Optimi Health Corp. announced that the dosing expected to be complete by the end of 2027.
Full Summary
|
ABBV AbbVie |
$255.00
+1.6% |
+2.4%
 |
Atogepant
Episodic Migraine
|
|
9/10/2026 - Top-line results
AbbVie announced positive topline results from the Phase 3 LUNA study, which evaluated atogepant, a …
Full Summary
|
OTLK Oncobiologics |
$0.66
+2.7% |
-39.9%
 |
LYTENAVA
For the Treatment of Wet AMD
|
|
9/10/2026 - Provided Update
Outlook Therapeutics, Inc. announced that Bob Jahr, Chief Executive Officer, recently participated …
Full Summary
|
VRCA Verrica Pharmaceuticals |
$4.95
-2.2% |
-2.8%
 |
VP-315
For the Treatment of Basal Cell Carcinoma
|
|
9/10/2026 - Poster Presentation
Verrica Pharmaceuticals Inc. announced that it will present posters on YCANTH® (VP-102), a therapy…
Full Summary
|
LYEL Lyell Immunopharma |
$12.20
-5.3% |
-13.9%
 |
LYL273
Metastatic Colorectal Cancer
|
|
9/10/2026 - Provided Update
Lyell Immunopharma, Inc announced successful completion of the planned technology transfer for LYL2…
Full Summary
|
IDYA IDEAYA Biosciences |
$37.45
-2.3% |
+1.3%
 |
Darovasertib
Non-metastatic uveal melanoma (UM)
|
|
9/9/2026 - Dose Update
IDEAYA Biosciences, Inc announced that the first patient has been dosed in OptimUM-11, a global Phas…
Full Summary
|
CMPS Compass Pathways |
$14.22
-6.3% |
|
COMP005
for treatment resistant depression (TRD).
|
Phase 3
|
9/9/2026 - Top-line results
Compass Pathways plc announced the topline 52-week results (Part C) from its Phase 3 COMP005 trial …
Full Summary
|
IRD Opus Genetics |
$6.07
+5.9% |
+61.4%
 |
OPGx-BEST1
For the treatment of bestrophin-1 (BEST1)-related IRD.
|
Phase 1/2
|
9/9/2026 - Positive Results
Opus Genetics, Inc announced positive 3- and 6-month results from the low-dose Cohort 1 of BIRD-1, i…
Full Summary
|
FATE Fate Therapeutics |
$2.33
-4.5% |
-14.3%
 |
FT819
Advanced B-cell Leukemias and Lymphomas
|
|
9/9/2026 - Clinical Data
Fate Therapeutics, Inc. announced clinical data from its off-the-shelf anti-CD19 CAR T-cell product…
Full Summary
|
RZLT Rezolute |
$4.17
+2.7% |
-11.3%
 |
Ersodetug
For Hypoglycemia Due to Congenital Hyperinsulinism
|
|
9/9/2026 - Provided Update
Rezolute, Inc. today provided an update on the status of the ongoing U.S. Food and Drug Administrat…
Full Summary
|
PYXS Pyxis Oncology |
$3.27
-3.3% |
+2.8%
 |
MICVO
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
|
|
9/9/2026 - Positive Data
Pyxis Oncology, Inc. announced positive updated data as of the August 18, 2026 data cutoff date fro…
Full Summary
|
INCY Incyte |
$123.28
-2.2% |
+2.1%
 |
Elraglusib (9-ING-41) + Retifanlimab + gemcitabine/nab-paclitaxel
First Line Therapy for Patients With Advanced Pancreatic Cancer
|
|
9/9/2026 - New preclinical data
Actuate Therapeutics, Inc. announced new preclinical data evaluating elraglusib in combination with …
Full Summary
|
RADX Radiopharm Theranostics |
$2.06
-1.0% |
-25.9%
 |
RAD301
Pancreatic Ductal Adenocarcinoma (PDAC).
|
Phase 1
|
9/9/2026 - Positive Data
Radiopharm Theranostics announced positive data from the Phase 1 imaging trial designed to evaluate…
Full Summary
|
AUTL Autolus Therapeutics |
$1.96
-3.4% |
-7.5%
 |
obe-cel
adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL).
|
RMAT Designation
|
9/9/2026 - Designation Grant
Autolus Therapeutics plc announced that the U.S. Food and Drug Administration (FDA) has granted reg…
Full Summary
|
PRTC PureTech Health |
$17.42
|
|
SPT-300
For the treatment of mood and anxiety disorders, including anxious depression
|
|
9/9/2026 - Top-line results
Seaport Therapeutics, Inc announced positive topline results from the Phase 1 Driving Simulation T…
Full Summary
|
COCP Cocrystal Pharma |
$1.23
-0.8% |
+9.8%
 |
CDI-988
For Pandemic Norovirus and Coronavirus
|
|
9/9/2026 - Provided Update
Cocrystal Pharma, Inc. announced that the last subject has been dosed in its Phase 1b norovirus cha…
Full Summary
|
COCP Cocrystal Pharma |
$1.23
-0.8% |
+9.8%
|
CDI-988
For Pandemic Norovirus and Coronavirus
|
Target date: LATE 2026
|
9/9/2026 - Results
Cocrystal Pharma, Inc announced that the Preliminary efficacy results expected in late 2026 or ea…
Full Summary
|
KZIA Novogen |
$11.01
-7.3% |
-13.9%
 |
PNOC035
for Recurrent Pediatric AT/RT Brain Cancer
|
Phase 2
|
9/9/2026 - Dose Update
Kazia Therapeutics Limited announced that the first patient has been dosed in Arm A of PNOC035, a Ph…
Full Summary
|
PRQR ProQR Therapeutics |
$1.94
-2.5% |
+4.3%
 |
AX-0811
for cholestatic liver diseases, including biliary atresia.
|
Phase 1
|
9/9/2026 - Dose Update
ProQR Therapeutics N.V announced that the first participant has been dosed in the Phase 1 clinical …
Full Summary
|
BMRN BioMarin Pharmaceutical |
$65.51
+1.7% |
-6.7%
 |
vosoritide
Children with achondroplasia
|
Phase 3
|
9/9/2026 - New Data
BioMarin Pharmaceutical Inc. announced new data from the Phase 3 CANOPY-HCH-3 study evaluating VOX…
Full Summary
|
ASND Ascendis Pharma A/S |
$261.23
+0.2% |
+2.3%
 |
TransCon CNP
In Children with Achondroplasia
|
|
9/9/2026 - Data
Ascendis Pharma A/S announced Week 52 data from the open-label sentinel cohort portion of the reAC…
Full Summary
|
UPB Upstream Bio |
$5.75
-3.5% |
-16.8%
 |
Verekitug
In Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2
|
9/8/2026 - Results
Upstream Bio, Inc. today presented results from the Phase 2 VALIANT clinical trial evaluating the sa…
Full Summary
|
BEAM Beam Therapeutics |
$24.37
-3.2% |
-8.8%
 |
BEAM-302
In Alpha-1 Antitrypsin Deficiency (AATD)
|
Phase 1/2
|
9/8/2026 - Clinical Data
Beam Therapeutics Inc. announced updated clinical data from the Phase 1/2 trial evaluating BEAM-302…
Full Summary
|
ROIV Roivant Sciences |
$40.94
-2.1% |
+13.2%
 |
Mosliciguat
In PH patients.
|
Phase 2
|
9/8/2026 - Positive Results
Roivant announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat f…
Full Summary
|
BLTE Belite Bio |
$175.07
-4.4% |
-2.2%
 |
Tinlarebant
In Stargardt Disease
|
|
9/8/2026 - New Drug Submissions
Belite Bio, Inc announced the submission of a New Drug Application (NDA) to the Ministry of Health,…
Full Summary
|
BMY Bristol Myers Squibb |
$63.76
-1.0% |
0.0%
 |
arlocabtagene
RRMM Patients
|
Phase 2
|
9/8/2026 - Positive Results
Bristol Myers Squibb announced positive Phase 2 results from the registrational QUINTESSENTIAL tria…
Full Summary
|
VOR Vor Biopharma |
$22.34
-3.9% |
|
telitacicept
Sjögren's Disease
|
Phase 3
|
9/8/2026 - Enrollment Completion
Vor Bio announced the completion of enrollment in UPSTREAM MG, its global Phase 3 registrational tri…
Full Summary
|
VOR Vor Biopharma |
$22.34
-3.9% |
|
telitacicept
Sjögren's Disease
|
Target date: H1 2027
|
9/8/2026 - Top-line results
Vor Bio announced Topline results from the 24-week primary endpoint remain expected in the first ha…
Full Summary
|
GLUE Monte Rosa Therapeutics |
$14.32
+0.4% |
-10.2%
 |
MRT-6160
To treat multiple T-cell and/or Th17 mediated autoimmune and inflammatory diseases, including ulcerative colitis (UC).
|
Phase 2
|
9/8/2026 - Provided Update
Monte Rosa Therapeutics, Inc. announced that its collaborator Novartis has initiated a Phase 2 cli…
Full Summary
|
DFTX Definium Therapeutics |
$37.73
-0.7% |
-11.8%
 |
DT120 ODT
For Major Depressive Disorder
|
Breakthrough Therapy
|
9/8/2026 - Designation Grant
Definium Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted B…
Full Summary
|
NKTX Nkarta |
$2.81
-3.4% |
+17.6%
 |
NKX019
Relapsed/refractory B cell malignancies
|
|
9/8/2026 - Provided Update
Nkarta, Inc. announced its selection for three scientific presentations at ACR Convergence 2026 bei…
Full Summary
|
XFOR X4 Pharmaceuticals |
$3.40
-5.6% |
-20.7%
 |
Mavorixafor
In people diagnosed with idiopathic, cyclic, or congenital neutropenia.
|
Phase 3
|
9/8/2026 - positive Outcome
X4 Pharmaceuticals announced the positive outcome of its Type C Meeting with the U.S. Food and Drug …
Full Summary
|
ARTV Artiva Biotherapeutics |
$10.42
-3.4% |
-9.6%
 |
AlloNK
in refractory rheumatoid arthritis
|
|
9/8/2026 - Provided Update
Artiva Biotherapeutics, Inc. today provided an update on anticipated data disclosures and developmen…
Full Summary
|
BIVI BioVie |
$1.91
-3.0% |
+22.4%
 |
Bezisterim
For Parkinson's Disease Patients
|
Phase 3
|
9/8/2026 - Provided Update
BioVie Inc. announced next stage of engagement with the Food and Drug Administration (FDA) to advanc…
Full Summary
|
BCTX Briacell Therap |
$3.60
-0.8% |
+5.6%
 |
Bria-IMT
Metastatic breast cancer (breast cancer that has spread beyond the breast)
|
|
9/8/2026 - Provided Update
BriaCell Therapeutics Corp announced that Memorial Sloan Kettering Cancer Center (MSK) has joined B…
Full Summary
|
DYN Dyne Therapeutics |
$18.42
-4.0% |
-29.6%
 |
DYNE-101
Designed to enable targeted muscle tissue delivery with the goal of reducing toxic DMPK RNA in the nucleus
|
|
9/8/2026 - Additional data
Dyne Therapeutics, Inc. announced that it will present additional one-year clinical data from the P…
Full Summary
|
DYN Dyne Therapeutics |
$18.42
-4.0% |
-29.6%
|
DYNE-101
Designed to enable targeted muscle tissue delivery with the goal of reducing toxic DMPK RNA in the nucleus
|
Target date: Q1 2027
|
9/8/2026 - Top-line data
Dyne Therapeutics, Inc. announced that the Topline data from the ACHIEVE REC are on track for Q1 20…
Full Summary
|
AVLN Avalyn Pharma |
$34.67
-3.4% |
-7.2%
 |
AP01
Patients with Progressive Pulmonary Fibrosis
|
|
9/8/2026 - New Data
Avalyn Pharma Inc. announced new data demonstrating predicted aerosol distribution of AP01 and surv…
Full Summary
|
BIOA BioAge Labs |
$8.65
-5.7% |
-17.5%
 |
BGE-102
For the treatment of obesity.
|
|
9/8/2026 - Dose Update
BioAge Labs, Inc. announced that the first participant has been dosed in QUELL-DME, a randomized, co…
Full Summary
|
NTLA Intellia Therapeutics |
$11.93
-2.3% |
-1.3%
 |
onvo-z
hereditary angioedema
|
BLA
|
9/8/2026 - FDA Accepted
Intellia Therapeutics, today announced the U.S. Food and Drug Administration (FDA) has accepted the…
Full Summary
|
NTLA Intellia Therapeutics |
$11.93
-2.3% |
-1.3%
|
onvo-z
hereditary angioedema
|
BLA
Target date: March 10, 2027
|
9/8/2026 - PDUFA Date
Intellia Therapeutics, announced that the PDUFA target action date of March 10, 2027
Full Summary
|
QNRX Quoin Pharmaceuticals |
$6.90
-1.0% |
+17.1%
 |
QRX003
Nethertons Syndrome
|
RPD Designation
|
9/8/2026 - Designation Grant
Quoin Pharmaceuticals Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted R…
Full Summary
|
BBIO BridgeBio Pharma |
$72.50
-4.7% |
-13.5%
 |
BBO-8520
Inhibitor of KRASG12C (ON) state.
|
|
9/8/2026 - Clinical Data
BridgeBio Oncology Therapeutics, Inc announced new clinical data for KRASG12C inhibitor BBO-8520 an…
Full Summary
|
ASND Ascendis Pharma A/S |
$261.23
+0.2% |
+2.3%
|
TransCon CNP
In Children with Achondroplasia
|
|
9/7/2026 - Data
Ascendis Pharma A/S announced it will share the latest data from its Endocrinology Rare Disease prog…
Full Summary
|
NYXH Nyxoah |
$1.50
-1.3% |
-5.1%
 |
Genio
For the Treatment of Obstructive Sleep Apnea
|
|
9/7/2026 - Provided Update
Nyxoah SA announced that the first patient has been implanted in BREATHE, the Company’s U.S. post-a…
Full Summary
|
ROIV Roivant Sciences |
$40.94
-2.1% |
+13.2%
|
Mosliciguat
In PH patients.
|
Phase 2
|
9/6/2026 - Presentation
Pulmovant announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmo…
Full Summary
|
RNTX Rein Therapeutics |
$0.78
-5.6% |
-3.0%
 |
LTI-03
In Idiopathic Pulmonary Fibrosis
|
|
9/4/2026 - Late Breaking Presentation
Rein Therapeutics announced that it will present a late-breaking poster at the European Respiratory…
Full Summary
|
IONS Ionis Pharmaceuticals |
$55.65
-0.7% |
-1.6%
 |
Pelacarsen
Cardiovascular disease and elevated levels of Lp(a)
|
Phase 3
|
9/4/2026 - updated results
Royalty Pharma plc announced an update on Novartis’ Phase 3 results from the HORIZON outcomes trial …
Full Summary
|
GH Guardant Health |
$159.03
-2.3% |
-3.7%
 |
Guardant360
Advanced solid tumors.
|
|
9/4/2026 - FDA approved
Guardant Health, Inc announced that the U.S. Food and Drug Administration (FDA) has approved Guarda…
Full Summary
|
INBX Inhibrx Biosciences |
$111.42
-1.3% |
+13.3%
 |
INBRX-106
refractory or relapsed non-small cell lung cancer (NSCLC) in combination with Keytruda.
|
|
9/4/2026 - Presentation
Inhibrx Biosciences, Inc. announced that it will host a live webcast presentation on Tuesday, Septe…
Full Summary
|
BIIB Biogen |
$215.43
+2.2% |
+3.1%
 |
LEQEMBI® (lecanemab-irmb)
Treatment of Alzheimer's Disease
|
National Medical Products Administration
|
9/3/2026 - Approved
Eisai Co., Ltd. and Biogen Inc. announced today that the National Medical Products Administration (N…
Full Summary
|
INSM Insmed |
$127.28
-1.2% |
-3.8%
 |
ARIKAYCE®
IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC
|
|
9/3/2026 - Abstract Presentation
nsmed Incorporated announced that five abstracts highlighting data from its respiratory portfolio h…
Full Summary
|
CCCC C4 Therapeutics |
$3.40
-1.2% |
-12.8%
 |
cemsidomide
IKZF1/3 Degrader
|
|
9/3/2026 - New Data
C4 Therapeutics, Inc. announced that new biomarker data on the immunomodulatory effects of cemsido…
Full Summary
|
CLYM Climb Bio |
$14.95
-0.7% |
+3.9%
 |
CLYM116
for IgAN
|
|
9/3/2026 - Positive Data
Climb Bio, Inc. announced positive initial data from the ongoing Phase 1 trial evaluating CLYM116, …
Full Summary
|
DYN Dyne Therapeutics |
$18.42
-4.0% |
-29.6%
|
DYNE-253
for Duchenne Muscular Dystrophy
|
|
9/3/2026 - Data Presentation
Dyne Therapeutics, Inc. announced that it will present preclinical data supporting the ongoing deve…
Full Summary
|
HRMY Harmony Biosciences |
$41.10
-1.2% |
+3.3%
 |
EPX-100
treatment of Dravet syndrome
|
|
9/3/2026 - Data Presentation
Harmony Biosciences Holdings, Inc announced that it will present encore data from the company’s inv…
Full Summary
|
LQDA Liquidia |
$67.85
-1.8% |
-13.9%
 |
YUTREPIA
Inhalation Powder
|
Fast Track
|
9/3/2026 - Designation Grant
Liquidia Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Fast Tr…
Full Summary
|
ABBV AbbVie |
$255.00
+1.6% |
+2.4%
|
etentamig
in patients with triple-class exposed (proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody) relapsed/refractory multiple myeloma (RRMM).
|
Phase 3
|
9/3/2026 - Top-line results
AbbVie announced positive topline results from the Phase 3 CERVINO study1 evaluating etentamig, an i…
Full Summary
|
MIST Milestone Pharmaceuticals |
$1.05
-1.9% |
-6.7%
 |
Etripamil
For Treatment in Paroxysmal Supraventricular Tachycardia
|
|
9/3/2026 - Approved
Milestone® Pharmaceuticals Inc announced that China’s National Medical Products Administration (NMP…
Full Summary
|
IONS Ionis Pharmaceuticals |
$55.65
-0.7% |
-1.6%
|
Zilganersen
for the treatment of children and adults Alexander disease (AxD).
|
|
9/3/2026 - FDA approved
Ionis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approve…
Full Summary
|
STOK Stoke Therapeutics |
$29.34
-1.9% |
-11.0%
 |
zorevunersen
For the treatment of Dravet syndrome with a confirmed mutation,
|
|
9/3/2026 - Presentation
Stoke Therapeutics, Inc. and Biogen Inc announced presentations of data at the 16th European Epilep…
Full Summary
|
UTHR United Therapeutics |
$503.86
-0.6% |
-1.5%
 |
Tyvaso (Treprostinil)
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)
|
supplemental New Drug Application (sNDA)
|
9/2/2026 - FDA Accepted
United Therapeutics Corporation announced that the FDA has accepted the supplemental New Drug App…
Full Summary
|
IRD Opus Genetics |
$6.07
+5.9% |
+61.4%
|
OPGx-BEST1
For the treatment of bestrophin-1 (BEST1)-related IRD.
|
Phase 1/2
|
9/2/2026 - Top-line data
Opus Genetics, Inc announced plans to present topline clinical data from Cohort 1 of its Phase 1/2 …
Full Summary
|
QURE uniQure |
$44.47
-3.3% |
-1.5%
 |
AMT-130
Huntington's Disease
|
BLA
|
9/2/2026 - BLA Filing
uniQure N.V announced the submission of a Biologics License Application (BLA) to the United States (…
Full Summary
|
TEVA Teva Pharmaceutical Industries |
$36.34
-1.4% |
-1.4%
 |
TEV ‘408
anti-IL-15 monoclonal antibody
|
|
9/2/2026 - Top-line results
Teva Pharmaceutical announced positive topline results from an ongoing Phase 2a study of TEV ‘408, …
Full Summary
|
TCRX TScan Therapeutics |
$0.32
-3.7% |
-58.9%
 |
TSC-101
Solid Tumors
|
|
9/2/2026 - Provided Update
TScan Therapeutics, Inc. announced it is strategically reorganizing to prioritize its in vivo solid …
Full Summary
|
BBIO BridgeBio Pharma |
$72.50
-4.7% |
-13.5%
|
Infigratinib PROPEL3
Infigratinib in Children with Achondroplasia
|
|
9/2/2026 - Orphan Drug Filing
BridgeBio Pharma, Inc. announced today that one late-breaking oral presentation on the impact of ora…
Full Summary
|
SRRK Scholar Rock |
$55.67
+1.9% |
+3.4%
 |
Apitegromab
Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
|
Fast Track
|
9/2/2026 - Designation Grant
Scholar Rock announced that the FDA has granted Fast Track and Orphan Drug designations to apitegro…
Full Summary
|
SRRK Scholar Rock |
$55.67
+1.9% |
+3.4%
|
Apitegromab
Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
|
Orphan Drug
|
9/2/2026 - Designation Grant
Scholar Rock announced that the FDA has granted Fast Track and Orphan Drug designations to apitegro…
Full Summary
|
SLS SELLAS Life Sciences Group |
$13.49
-3.3% |
+14.6%
 |
SLS009
For Treatment of Acute Myeloid Leukemia
|
|
9/2/2026 - Abstract
SELLAS Life Sciences Group, announced that three abstracts evaluating SLS009 (tambiciclib), a poten…
Full Summary
|
RARE Ultragenyx Pharmaceutical |
$14.40
+0.6% |
-46.4%
 |
GTX-102
Angelman Syndrome
|
Phase 3
|
9/2/2026 - Results
Ultragenyx Pharmaceutical announced results from the Phase 3 Aspire study for apazunersen (GTX-102…
Full Summary
|
OCGN Ocugen |
$1.03
-3.8% |
-26.8%
 |
OCU410
Dry Age-related Macular Degeneration (Dry AMD)
|
Phase 3
|
9/1/2026 - Dose Update
Ocugen, Inc announced that the first patient was dosed in the global Phase 3 registrational trial o…
Full Summary
|
ACET Adicet Bio |
$9.53
-0.1% |
+15.4%
 |
ADI-001
B cell non-Hodgkin's lymphoma (NHL)
|
Phase 1
|
9/1/2026 - Provided Update
Adicet Bio, Inc announced completion of the last patient visit for the planned Phase 1 safety and ef…
Full Summary
|
BLSM BlossomHill Therapeutics |
$21.51
-2.2% |
+32.5%
 |
BH-30643
Treatment of Advanced EGFR C797S-positive NSCLC
|
Phase 1/2
|
9/1/2026 - Updated data
BlossomHill Therapeutics, Inc. announced that updated data from the ongoing Phase 1/2 SOLARA trial …
Full Summary
|
UPB Upstream Bio |
$5.75
-3.5% |
-16.8%
|
Verekitug
In Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3
|
9/1/2026 - Provided Update
Upstream Bio, Inc. announced its pivotal Phase 3 development plans for verekitug in severe asthma an…
Full Summary
|
KYMR Kymera Therapeutics |
$117.00
+1.4% |
+2.6%
 |
KT-621
A potential oral treatment for asthma and other TH2 respiratory diseases.
|
|
9/1/2026 - Poster Presentation
Kymera Therapeutics, announced that the Company will present two posters featuring previously repor…
Full Summary
|
NTRA Natera |
$326.14
-1.3% |
+3.2%
 |
Signatera
MRD Test for cancer therapies
|
|
9/1/2026 - Publication
Natera, Inc. announced the publication of new data in Blood Neoplasia, validating the prognostic and…
Full Summary
|
KZIA Novogen |
$11.01
-7.3% |
-13.9%
|
Paxalisib
Atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly-aggressive childhood brain cancer
|
|
9/1/2026 - New Data
Kazia Therapeutics Limited announced new preclinical and translational data showing that its lead a…
Full Summary
|
ALMS Alumis |
$9.90
+1.0% |
-61.3%
 |
envudeucitinib
in Moderate-to-Severe Plaque Psoriasis
|
Phase 2b
|
9/1/2026 - Endpoint Missed
Alumis Inc. announced that its Phase 2b LUMUS trial of envudeucitinib for the treatment of moderate-…
Full Summary
|
STOK Stoke Therapeutics |
$29.34
-1.9% |
-11.0%
|
zorevunersen
For the treatment of Dravet syndrome with a confirmed mutation,
|
|
9/1/2026 - Presentation
Stoke Therapeutics, Inc and Biogen Inc announced presentations of data at the 16th European Epilep…
Full Summary
|
LIFE Ethos Technologies Inc. Class A Common Stock |
$38.85
-2.2% |
+15.7%
 |
Efzofitimod
Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
|
|
9/1/2026 - Provided Update
aTyr Pharma, Inc. today provided an update on the expected timing of a response from the U.S. Food a…
Full Summary
|
RARE Ultragenyx Pharmaceutical |
$14.40
+0.6% |
-46.4%
|
DTX401
Glycogen Storage Disease Type Ia (GSDIa)
|
Phase 3
|
9/1/2026 - Publication
Ultragenyx Pharmaceutical announced the publication of 96-week data from its Phase 3 study of GENGL…
Full Summary
|
IDYA IDEAYA Biosciences |
$37.45
-2.3% |
+1.3%
|
IDE849
In Solid Tumors
|
FDA Type C Meeting
|
8/31/2026 - FDA Meeting
IDEAYA Biosciences, Inc announced a successful FDA Type C meeting to determine the Phase 3 registr…
Full Summary
|
JAZZ Jazz Pharmaceuticals |
$240.48
-0.3% |
-3.4%
 |
Ziihera
For the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
|
Phase 3
|
8/31/2026 - Top-line results
BeOne Medicines Ltd. announced positive topline results from the second interim analysis (IA2) of …
Full Summary
|
KPTI Karyopharm Therapeutics |
$1.62
-4.1% |
-20.2%
 |
XPOVIO (selinexor) + Jakafi (ruxolitinib)
Naïve Myelofibrosis
|
supplemental New Drug Application (sNDA)
|
8/31/2026 - sNDA Submission
Karyopharm Therapeutics Inc. announced that it has submitted a supplemental New Drug Application (s…
Full Summary
|
AXSM Axsome Therapeutics |
$211.12
+0.2% |
-1.6%
 |
AXS-05
Major Depressive Disorder
|
Phase 3
|
8/31/2026 - Dose Update
Axsome Therapeutics, Inc announced that the first patient has been dosed in the SUMMIT Phase 3 tria…
Full Summary
|
LLY Eli Lilly and Company |
$1,122.74
-0.1% |
-7.9%
 |
Taltz
adults with psoriasis and obesity or overweight
|
Phase 3b
|
8/31/2026 - Results
Eli Lilly and Company announced 52-week results from TOGETHER-PsO and TOGETHER-PsA, two novel open…
Full Summary
|
